Comparison of Outcomes After Percutaneous Coronary Intervention for Chronic Total Occlusion Using Everolimus- Versus Sirolimus- Versus Paclitaxel-Eluting Stents (from the Korean National Registry of Chronic Total Occlusion Intervention)

Min Ho Lee, Joo M. Lee, Si Hyuck Kang, Chang Hwan Yoon, Yangsoo Jang, Cheol W. Yu, Hun S. Park, Seunghwan Lee, Seung Ho Hur, Moo H. Kim, Seung Woon Rha, Hyeon Cheol Gwon, In Ho Chae, Hyo Soo Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

For the treatment of chronic total occlusion (CTO), the efficacy and safety of the everolimus-eluting stent (EES) remain less well defined. Also, there are limited data for the predictors of outcome after CTO intervention. The purpose of this study was to compare clinical outcomes of the EES with the first-generation drug-eluting stent (DES) in CTO intervention and to investigate the predictors of clinical outcome. The Korean National Registry of CTO Intervention is a retrospective cohort of 26 centers from the past 5 years. The primary end point was major adverse cardiovascular events (MACE) defined as a composite of cardiac death, nonfatal myocardial infarction, and target lesion revascularization. Of the 1,754 all-comer patients, 1,509 patients (EES 311, sirolimus-eluting stent [SES] 642, paclitaxel-eluting stent 556) were finally analyzed after excluding 245 patients (mixed DESs in 46 and follow-up loss in 199). In the inverse probability weighting-adjusted population, the 1-year MACE rate of the EES was comparable with that of the SES (5.8% vs 3.4%, p = 0.796) and the paclitaxel-eluting stent (5.8% vs 6.9%, p = 0.740). Each component of MACE was also comparable among the 3 stents. Importantly, the independent predictors of MACE were diabetes mellitus, previous congestive heart failure, and left circumflex CTO. In conclusion, for the first time in the largest CTO cohort, the EES showed good 1-year clinical outcomes that were comparable with the SES. Independent predictors of MACE after CTO intervention were clinical factors (diabetes and congestive heart failure) and lesion location.

Original languageEnglish
Article number21108
Pages (from-to)195-203
Number of pages9
JournalAmerican Journal of Cardiology
Volume116
Issue number2
DOIs
Publication statusPublished - 2015 Jul 15

Fingerprint

Sirolimus
Percutaneous Coronary Intervention
Paclitaxel
Stents
Registries
Everolimus
Heart Failure
Drug-Eluting Stents
Diabetes Mellitus
Myocardial Infarction
Safety

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Lee, Min Ho ; Lee, Joo M. ; Kang, Si Hyuck ; Yoon, Chang Hwan ; Jang, Yangsoo ; Yu, Cheol W. ; Park, Hun S. ; Lee, Seunghwan ; Hur, Seung Ho ; Kim, Moo H. ; Rha, Seung Woon ; Gwon, Hyeon Cheol ; Chae, In Ho ; Kim, Hyo Soo. / Comparison of Outcomes After Percutaneous Coronary Intervention for Chronic Total Occlusion Using Everolimus- Versus Sirolimus- Versus Paclitaxel-Eluting Stents (from the Korean National Registry of Chronic Total Occlusion Intervention). In: American Journal of Cardiology. 2015 ; Vol. 116, No. 2. pp. 195-203.
@article{814233d351f14a4bbb9b5e8e3339b487,
title = "Comparison of Outcomes After Percutaneous Coronary Intervention for Chronic Total Occlusion Using Everolimus- Versus Sirolimus- Versus Paclitaxel-Eluting Stents (from the Korean National Registry of Chronic Total Occlusion Intervention)",
abstract = "For the treatment of chronic total occlusion (CTO), the efficacy and safety of the everolimus-eluting stent (EES) remain less well defined. Also, there are limited data for the predictors of outcome after CTO intervention. The purpose of this study was to compare clinical outcomes of the EES with the first-generation drug-eluting stent (DES) in CTO intervention and to investigate the predictors of clinical outcome. The Korean National Registry of CTO Intervention is a retrospective cohort of 26 centers from the past 5 years. The primary end point was major adverse cardiovascular events (MACE) defined as a composite of cardiac death, nonfatal myocardial infarction, and target lesion revascularization. Of the 1,754 all-comer patients, 1,509 patients (EES 311, sirolimus-eluting stent [SES] 642, paclitaxel-eluting stent 556) were finally analyzed after excluding 245 patients (mixed DESs in 46 and follow-up loss in 199). In the inverse probability weighting-adjusted population, the 1-year MACE rate of the EES was comparable with that of the SES (5.8{\%} vs 3.4{\%}, p = 0.796) and the paclitaxel-eluting stent (5.8{\%} vs 6.9{\%}, p = 0.740). Each component of MACE was also comparable among the 3 stents. Importantly, the independent predictors of MACE were diabetes mellitus, previous congestive heart failure, and left circumflex CTO. In conclusion, for the first time in the largest CTO cohort, the EES showed good 1-year clinical outcomes that were comparable with the SES. Independent predictors of MACE after CTO intervention were clinical factors (diabetes and congestive heart failure) and lesion location.",
author = "Lee, {Min Ho} and Lee, {Joo M.} and Kang, {Si Hyuck} and Yoon, {Chang Hwan} and Yangsoo Jang and Yu, {Cheol W.} and Park, {Hun S.} and Seunghwan Lee and Hur, {Seung Ho} and Kim, {Moo H.} and Rha, {Seung Woon} and Gwon, {Hyeon Cheol} and Chae, {In Ho} and Kim, {Hyo Soo}",
year = "2015",
month = "7",
day = "15",
doi = "10.1016/j.amjcard.2015.04.010",
language = "English",
volume = "116",
pages = "195--203",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "2",

}

Comparison of Outcomes After Percutaneous Coronary Intervention for Chronic Total Occlusion Using Everolimus- Versus Sirolimus- Versus Paclitaxel-Eluting Stents (from the Korean National Registry of Chronic Total Occlusion Intervention). / Lee, Min Ho; Lee, Joo M.; Kang, Si Hyuck; Yoon, Chang Hwan; Jang, Yangsoo; Yu, Cheol W.; Park, Hun S.; Lee, Seunghwan; Hur, Seung Ho; Kim, Moo H.; Rha, Seung Woon; Gwon, Hyeon Cheol; Chae, In Ho; Kim, Hyo Soo.

In: American Journal of Cardiology, Vol. 116, No. 2, 21108, 15.07.2015, p. 195-203.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Comparison of Outcomes After Percutaneous Coronary Intervention for Chronic Total Occlusion Using Everolimus- Versus Sirolimus- Versus Paclitaxel-Eluting Stents (from the Korean National Registry of Chronic Total Occlusion Intervention)

AU - Lee, Min Ho

AU - Lee, Joo M.

AU - Kang, Si Hyuck

AU - Yoon, Chang Hwan

AU - Jang, Yangsoo

AU - Yu, Cheol W.

AU - Park, Hun S.

AU - Lee, Seunghwan

AU - Hur, Seung Ho

AU - Kim, Moo H.

AU - Rha, Seung Woon

AU - Gwon, Hyeon Cheol

AU - Chae, In Ho

AU - Kim, Hyo Soo

PY - 2015/7/15

Y1 - 2015/7/15

N2 - For the treatment of chronic total occlusion (CTO), the efficacy and safety of the everolimus-eluting stent (EES) remain less well defined. Also, there are limited data for the predictors of outcome after CTO intervention. The purpose of this study was to compare clinical outcomes of the EES with the first-generation drug-eluting stent (DES) in CTO intervention and to investigate the predictors of clinical outcome. The Korean National Registry of CTO Intervention is a retrospective cohort of 26 centers from the past 5 years. The primary end point was major adverse cardiovascular events (MACE) defined as a composite of cardiac death, nonfatal myocardial infarction, and target lesion revascularization. Of the 1,754 all-comer patients, 1,509 patients (EES 311, sirolimus-eluting stent [SES] 642, paclitaxel-eluting stent 556) were finally analyzed after excluding 245 patients (mixed DESs in 46 and follow-up loss in 199). In the inverse probability weighting-adjusted population, the 1-year MACE rate of the EES was comparable with that of the SES (5.8% vs 3.4%, p = 0.796) and the paclitaxel-eluting stent (5.8% vs 6.9%, p = 0.740). Each component of MACE was also comparable among the 3 stents. Importantly, the independent predictors of MACE were diabetes mellitus, previous congestive heart failure, and left circumflex CTO. In conclusion, for the first time in the largest CTO cohort, the EES showed good 1-year clinical outcomes that were comparable with the SES. Independent predictors of MACE after CTO intervention were clinical factors (diabetes and congestive heart failure) and lesion location.

AB - For the treatment of chronic total occlusion (CTO), the efficacy and safety of the everolimus-eluting stent (EES) remain less well defined. Also, there are limited data for the predictors of outcome after CTO intervention. The purpose of this study was to compare clinical outcomes of the EES with the first-generation drug-eluting stent (DES) in CTO intervention and to investigate the predictors of clinical outcome. The Korean National Registry of CTO Intervention is a retrospective cohort of 26 centers from the past 5 years. The primary end point was major adverse cardiovascular events (MACE) defined as a composite of cardiac death, nonfatal myocardial infarction, and target lesion revascularization. Of the 1,754 all-comer patients, 1,509 patients (EES 311, sirolimus-eluting stent [SES] 642, paclitaxel-eluting stent 556) were finally analyzed after excluding 245 patients (mixed DESs in 46 and follow-up loss in 199). In the inverse probability weighting-adjusted population, the 1-year MACE rate of the EES was comparable with that of the SES (5.8% vs 3.4%, p = 0.796) and the paclitaxel-eluting stent (5.8% vs 6.9%, p = 0.740). Each component of MACE was also comparable among the 3 stents. Importantly, the independent predictors of MACE were diabetes mellitus, previous congestive heart failure, and left circumflex CTO. In conclusion, for the first time in the largest CTO cohort, the EES showed good 1-year clinical outcomes that were comparable with the SES. Independent predictors of MACE after CTO intervention were clinical factors (diabetes and congestive heart failure) and lesion location.

UR - http://www.scopus.com/inward/record.url?scp=84931577064&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931577064&partnerID=8YFLogxK

U2 - 10.1016/j.amjcard.2015.04.010

DO - 10.1016/j.amjcard.2015.04.010

M3 - Article

C2 - 26001819

AN - SCOPUS:84931577064

VL - 116

SP - 195

EP - 203

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 2

M1 - 21108

ER -